Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics announced more than 20 patients pre-identified for REO 033 colorectal cancer trial and scheduled Type D meeting with the FDA.
June 16, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.
June 02, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.
June 01, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.
May 22, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
May 04, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics announced new data in metastatic colorectal cancer, demonstrating 3-4x improvement in duration response vs. historical 4-6 month benchmark.
April 27, 2026 08:10 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with SCAC.
April 06, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an...
April 01, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Completes Domicile Change to the United States

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...
March 19, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in...